FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Sci Rep / Modulation of stress and immune response by Amblyomin-X resu...
Scientific reports2020; 10(1); 6388; doi: 10.1038/s41598-020-63275-2

Modulation of stress and immune response by Amblyomin-X results in tumor cell death in a horse melanoma model.

Abstract: We have investigated Amblyomin-X-treated horse melanomas to better understand its mode of action through transcriptome analysis and the in vivo model. Amblyomin-X is a Kunitz-type homologous protein that selectively leads to the death of tumor cells via ER stress and apoptosis, currently under investigation as a new drug candidate for cancer treatment. Melanomas are immunogenic tumors, and a better understanding of the immune responses is warranted. Equine melanomas are spontaneous and not so aggressive as human melanomas are, as this study shows that the in vivo treatment of encapsulated horse melanoma tumors led to a significant reduction in the tumor size or even the complete disappearance of the tumor mass through intratumoral injections of Amblyomin-X. Transcriptome analysis identified ER- and mitochondria-stress, modulation of the innate immune system, apoptosis, and possibly immunogenic cell death activation. Interactome analysis showed that Amblyomin-X potentially interacts with key elements found in transcriptomics. Taken together, Amblyomin-X modulated the tumor immune microenvironment in different ways, at least contributing to induce tumor cell death.
Get Full Text
Publication Date: 2020-04-14 PubMed ID: 32286411PubMed Central: PMC7156751DOI: 10.1038/s41598-020-63275-2Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article investigates how Amblyomin-X, a protein currently under investigation for cancer treatment, affects melanomas in horses, resulting in tumor cell death. The study particularly sheds light on the effects of Amblyomin-X on stress, immunity, and cancer cell death and its potential as a novel cancer treatment candidate.

Introduction

  • This study discusses the effects of a drug candidate called Amblyomin-X on melanomas (a type of skin cancer) in horses.
  • Amblyomin-X is a Kunitz-type protein that selectively induces tumor cell death through endoplasmic reticulum (ER) stress and apoptosis (cell death).

Method

  • Scientists have used transcriptome analysis and in-vivo models to understand the mode of action of Amblyomin-X.
  • Equine melanomas, unlike human melanomas, are less aggressive and occur naturally, making them an ideal study model.
  • In this study, encapsulated horse melanoma tumors were treated with intratumoral injections of Amblyomin-X to observe the effects on tumor size and mass.

Findings

  • The treatment led to a significant shrinkage or even complete disappearance of the tumor mass, indicating effective tumor cell death.
  • Transcriptome analysis identified that Amblyomin-X induces ER and mitochondrial stress, orchestrates the innate immune system, and potentially activates immunogenic cell death.
  • Interactome analysis, which is the study of the entire set of molecular interactions in cells, demonstrated that Amblyomin-X potentially interacts with critical elements discovered in the transcriptome analysis

Conclusion

  • The study found that Amblyomin-X modulates the tumor immune microenvironment in various ways, contributing to tumor cell death.
  • These findings suggest that Amblyomin-X has the potential to be developed into a new drug treatment for cancer given its effect on stress, immunity, and cancer cell deaths.

Cite This Article

APA
Lichtenstein F, Iqbal A, de Lima Will SEA, Bosch RV, DeOcesano-Pereira C, Goldfeder MB, Chammas R, Trufen CEM, Morais KLP, de Souza JG, Natalino RJM, de Azevedo IJ, Nishiyama Junior MY, Oliveira U, Alves FIA, Araujo JM, Lobba ARM, Chudzinski-Tavassi AM. (2020). Modulation of stress and immune response by Amblyomin-X results in tumor cell death in a horse melanoma model. Sci Rep, 10(1), 6388. https://doi.org/10.1038/s41598-020-63275-2

Publication

Scientific reports
ISSN: 2045-2322
NlmUniqueID: 101563288
Country: England
Language: English
Volume: 10
Issue: 1
Pages: 6388

Researcher Affiliations

Lichtenstein, Flavio
  • Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil.
  • CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil.
Iqbal, Asif
  • Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil.
  • CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil.
de Lima Will, Sonia Elisabete Alves
  • Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil.
  • CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil.
Bosch, Rosemary Viola
  • Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil.
  • CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil.
DeOcesano-Pereira, Carlos
  • Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil.
  • CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil.
Goldfeder, Mauricio Barbugiani
  • Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil.
  • CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil.
Chammas, Roger
  • ICESP, Center for Translational Research in Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Trufen, Carlos Eduardo Madureira
  • Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil.
  • CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil.
Morais, Katia Luciano Pereira
  • Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil.
  • CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil.
de Souza, Jean Gabriel
  • Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil.
  • CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil.
Natalino, Renato Jose Mendonça
  • ICESP, Center for Translational Research in Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
de Azevedo, Inacio Junqueira
  • Laboratório Especial de Toxinologia Aplicada - CeTICS, Butantan Institute, São Paulo, Brazil.
Nishiyama Junior, Milton Yutaka
  • Laboratório Especial de Toxinologia Aplicada - CeTICS, Butantan Institute, São Paulo, Brazil.
Oliveira, Ursula
  • Laboratório Especial de Toxinologia Aplicada - CeTICS, Butantan Institute, São Paulo, Brazil.
Alves, Francisco Ivanio Arruda
  • Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil.
  • CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil.
Araujo, Jaqueline Mayara
  • Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil.
  • CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil.
Lobba, Aline Ramos Maia
  • Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil.
  • CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil.
Chudzinski-Tavassi, Ana Marisa
  • Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil. ana.chudzinski@butantan.gov.br.
  • CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil. ana.chudzinski@butantan.gov.br.

MeSH Terms

  • Animals
  • Antineoplastic Agents / therapeutic use
  • Arthropod Proteins / therapeutic use
  • Cell Death / drug effects
  • Drug Discovery
  • Horse Diseases / drug therapy
  • Horses
  • Male
  • Melanoma / drug therapy
  • Melanoma / veterinary
  • Salivary Proteins and Peptides / therapeutic use
  • Tumor Microenvironment / drug effects

Conflict of Interest Statement

The authors declare no competing interests.

References

This article includes 70 references
  1. Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification.. Vivo Athens Greece 2014;28:1005–1011.
    pubmed: 25398793
  2. American Institute for Cancer Research. Skin cancer statistics - World Cancer Research Fund. https://www.wcrf.org/dietandcancer/cancer-trends/skin-cancer-statistics (2019).
  3. American Institute for Cancer Research. Skin cancer - How diet, nutrition and physical activity affect skin cancer risk. https://www.wcrf.org/dietandcancer/skin-cancer (2019).
  4. Instituto Nacional de Câncer - INCA. Incidência de Câncer no Brasil - Estimativa 2018. (Instituto Nacional de Câncer José Alencar Gomes da Silva. Coordenação de Prevenção e Vigilância, 2017).
  5. Rausch MP, Hastings KT. Immune Checkpoint Inhibitors in the Treatment of Melanoma: From Basic Science to Clinical Application - Chapter 9. Cutaneous Melanoma: Etiology and Therapy 2017.
    pubmed: 29461774
  6. Smith SH, Goldschmidt MH, McManus PM. A Comparative Review of Melanocytic Neoplasms.. Vet. Pathol. 2002;39:651–678.
    doi: 10.1354/vp.39-6-651pubmed: 12450197google scholar: lookup
  7. Rissi DR, Fighera RA, Irigoyen LF, De Lacorte FD, Barros CSLde. Melanoma maligno anaplásico em um eqüino.. Ciênc. Rural 2008;38:2072–2075.
  8. Hodis E. A Landscape of Driver Mutations in Melanoma.. Cell 2012;150:251–263.
    doi: 10.1016/j.cell.2012.06.024pmc: PMC3600117pubmed: 22817889google scholar: lookup
  9. Zhao ZZ. Polymorphisms in the syntaxin 17 gene are not associated with human cutaneous malignant melanoma.. Melanoma Res. 2009;19:80–86.
    doi: 10.1097/CMR.0b013e328322fc45pmc: PMC3665505pubmed: 19209086google scholar: lookup
  10. Rosengren Pielberg G. A cis-acting regulatory mutation causes premature hair graying and susceptibility to melanoma in the horse.. Nat. Genet. 2008;40:1004–1009.
    doi: 10.1038/ng.185pubmed: 18641652google scholar: lookup
  11. van der Weyden L. Cross-species models of human melanoma: Cross-species models of human melanoma.. J. Pathol. 2016;238:152–165.
    doi: 10.1002/path.4632pmc: PMC4832391pubmed: 26354726google scholar: lookup
  12. Jiang L. Constitutive activation of the ERK pathway in melanoma and skin melanocytes in Grey horses.. BMC Cancer 2014;14.
    pmc: PMC4254013pubmed: 25413220
  13. Batista IFC. Expressed sequence tags (ESTs) from the salivary glands of the tick Amblyomma cajennense (Acari: Ixodidae). Toxicon 2008;51:823–834.
    doi: 10.1016/j.toxicon.2007.12.011pubmed: 18243270google scholar: lookup
  14. Branco VG. Amblyomin-X having a Kunitz-type homologous domain, is a noncompetitive inhibitor of FXa and induces anticoagulation in vitro and in vivo.. Biochim. Biophys. Acta BBA - Proteins Proteomics 2016;1864:1428–1435.
    doi: 10.1016/j.bbapap.2016.07.011pubmed: 27479486google scholar: lookup
  15. Maria DA. A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production.. Invest. New Drugs 2013;31:493–505.
    doi: 10.1007/s10637-012-9871-1pmc: PMC3644403pubmed: 22975862google scholar: lookup
  16. Chudzinski-Tavassi AM, Morais KLP, Pacheco MTF, Pasqualoto KFM, de Souza JG. Tick salivary gland as potential natural source for the discovery of promising antitumor drug candidates.. Biomed. Pharmacother. 2016;77:14–19.
    doi: 10.1016/j.biopha.2015.11.003pubmed: 26796259google scholar: lookup
  17. de Souza JG. Promising pharmacological profile of a Kunitz-type inhibitor in murine renal cell carcinoma model.. Oncotarget 2016;7.
    pmc: PMC5308724pubmed: 27566592
  18. Morais KLP. Amblyomin-X induces ER stress, mitochondrial dysfunction, and caspase activation in human melanoma and pancreatic tumor cell.. Mol. Cell. Biochem. 2016;415:119–131.
    doi: 10.1007/s11010-016-2683-4pmc: PMC4819916pubmed: 27015684google scholar: lookup
  19. Chudzinski-Tavassi AM. A new tick Kunitz type inhibitor, Amblyomin-X, induces tumor cell death by modulating genes related to the cell cycle and targeting the ubiquitin-proteasome system.. Toxicon 2010;56:1145–1154.
    doi: 10.1016/j.toxicon.2010.04.019pubmed: 20570593google scholar: lookup
  20. Akagi EM. Pro-apoptotic effects of Amblyomin-X in murine renal cell carcinoma “in vitro”.. Biomed. Pharmacother. 2012;66:64–69.
    doi: 10.1016/j.biopha.2011.11.015pubmed: 22281290google scholar: lookup
  21. Zanotto-Filho A, Braganhol E, Battastini AMO, Moreira JCF. Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling.. Invest. New Drugs 2012;30:2252–2262.
    doi: 10.1007/s10637-012-9804-zpubmed: 22367315google scholar: lookup
  22. Mehta-Shah N, Younes A. Novel Targeted Therapies in Diffuse Large B-Cell Lymphoma.. Semin. Hematol. 2015;52:126–137.
    doi: 10.1053/j.seminhematol.2015.01.007pubmed: 25805592google scholar: lookup
  23. Honma Y, Shimizu S, Takehara T, Harada M. Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.. J. Gastroenterol. 2014;49:517–526.
    doi: 10.1007/s00535-013-0796-zpubmed: 23543326google scholar: lookup
  24. Laporte AN. HDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial Sarcoma.. PLOS ONE 2017;12:e0169407.
    doi: 10.1371/journal.pone.0169407pmc: PMC5215898pubmed: 28056055google scholar: lookup
  25. Fernández Y. Differential Regulation of Noxa in Normal Melanocytes and Melanoma Cells by Proteasome Inhibition: Therapeutic Implications.. Cancer Res. 2005;65:6294–6304.
    doi: 10.1158/0008-5472.CAN-05-0686pubmed: 16024631google scholar: lookup
  26. Sorolla A. Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines: Effect of proteasome inhibitors on melanoma cells.. Br. J. Dermatol. 2008;158:496–504.
    doi: 10.1111/j.1365-2133.2007.08390.xpubmed: 18205878google scholar: lookup
  27. Reuland SN. ABT-737 synergizes with Bortezomib to kill melanoma cells.. Biol. Open. 2012;1:92–100.
    doi: 10.1242/bio.2011035pmc: PMC3507205pubmed: 23213401google scholar: lookup
  28. Selimovic D. Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells.. Cell. Signal. 2013;25:308–318.
    doi: 10.1016/j.cellsig.2012.10.004pubmed: 23079083google scholar: lookup
  29. Sidor-Kaczmarek J, Cichorek M, Spodnik JH, Wójcik S, Moryś J. Proteasome inhibitors against amelanotic melanoma.. Cell Biol. Toxicol. 2017;33:557–573.
    doi: 10.1007/s10565-017-9390-0pmc: PMC5658467pubmed: 28281027google scholar: lookup
  30. Croghan GA. A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: A phase 2 Consortium study.. Cancer 2010;116:3463–3468.
    doi: 10.1002/cncr.25191pmc: PMC3860743pubmed: 20564112google scholar: lookup
  31. Roeten MSF, Cloos J, Jansen G. Positioning of proteasome inhibitors in therapy of solid malignancies.. Cancer Chemother. Pharmacol. 2018;81:227–243.
    doi: 10.1007/s00280-017-3489-0pmc: PMC5778165pubmed: 29184971google scholar: lookup
  32. Cavo M. Current status of bortezomib in the treatment of multiple myeloma.. Curr. Hematol. Malig. Rep. 2007;2:128–137.
    doi: 10.1007/s11899-007-0018-ypubmed: 20425361google scholar: lookup
  33. Curran MP, McKeage K. Bortezomib: A Review of its Use in Patients with Multiple Myeloma.. Drugs 2009;69:859–888.
    doi: 10.2165/00003495-200969070-00006pubmed: 19441872google scholar: lookup
  34. Perez-Caballero D, Hatziioannou T, Zhang F, Cowan S, Bieniasz PD. Restriction of Human Immunodeficiency Virus Type 1 by TRIM-CypA Occurs with Rapid Kinetics and Independently of Cytoplasmic Bodies, Ubiquitin, and Proteasome Activity.. J. Virol. 2005;79:15567–15572.
    doi: 10.1128/JVI.79.24.15567-15572.2005pmc: PMC1316013pubmed: 16306627google scholar: lookup
  35. Gatzka M. Targeted Tumor Therapy Remixed—An Update on the Use of Small-Molecule Drugs in Combination Therapies.. Cancers 2018;10:155.
    doi: 10.3390/cancers10060155pmc: PMC6025289pubmed: 29794999google scholar: lookup
  36. Lub S. Novel strategies to target the ubiquitin proteasome system in multiple myeloma.. Oncotarget 2016;7.
    pmc: PMC4872730pubmed: 26695547
  37. Csardi G, Nepusz T. The igraph software package for complex network researc.. InterJournal Complex Systems 2006;1695.
  38. Herrin BR, Groeger AL, Justement LB. The Adaptor Protein HSH2 Attenuates Apoptosis in Response to Ligation of the B Cell Antigen Receptor Complex on the B Lymphoma Cell Line, WEHI-231.. J. Biol. Chem. 2005;280:3507–3515.
    doi: 10.1074/jbc.M407690200pubmed: 15569688google scholar: lookup
  39. Zsila F, Iwao Y. The drug binding site of human α1-acid glycoprotein: Insight from induced circular dichroism and electronic absorption spectra.. Biochim. Biophys. Acta BBA - Gen. Subj. 2007;1770:797–809.
    doi: 10.1016/j.bbagen.2007.01.009pubmed: 17321687google scholar: lookup
  40. Wang Y, Tong X, Ye X. Ndfip1 Negatively Regulates RIG-I–Dependent Immune Signaling by Enhancing E3 Ligase Smurf1-Mediated MAVS Degradation.. J. Immunol. 2012;189:5304–5313.
    doi: 10.4049/jimmunol.1201445pubmed: 23087404google scholar: lookup
  41. Yoo JC. SYT14L, especially its C2 domain, is involved in regulating melanocyte differentiation.. J. Dermatol. Sci. 2013;72:246–251.
    doi: 10.1016/j.jdermsci.2013.07.010pubmed: 23999003google scholar: lookup
  42. Pacheco MTF. Dynein Function and Protein Clearance Changes in Tumor Cells Induced by a Kunitz-Type Molecule, Amblyomin-X.. PLoS ONE 2014;9:e111907.
    doi: 10.1371/journal.pone.0111907pmc: PMC4257547pubmed: 25479096google scholar: lookup
  43. Schmidt MCB. Amblyomin-X, a recombinant Kunitz-type inhibitor, regulates cell adhesion and migration of human tumor cells.. Cell Adhes. Migr. 2018;1–10.
    pmc: PMC7527229pubmed: 30238848doi: 10.1080/19336918.2018.1516982google scholar: lookup
  44. Nabet BY. Exosome RNA Unshielding Couples Stromal Activation to Pattern Recognition Receptor Signaling in Cancer.. Cell 2017;170:352–366.e13.
    doi: 10.1016/j.cell.2017.06.031pmc: PMC6611169pubmed: 28709002google scholar: lookup
  45. Roulois D. DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts.. Cell 2015;162:961–973.
    doi: 10.1016/j.cell.2015.07.056pmc: PMC4843502pubmed: 26317465google scholar: lookup
  46. Silverman RH. Viral Encounters with 2′,5′-Oligoadenylate Synthetase and RNase L during the Interferon Antiviral Response.. J. Virol. 2007;81:12720–12729.
    doi: 10.1128/JVI.01471-07pmc: PMC2169107pubmed: 17804500google scholar: lookup
  47. Yu X. Activation of the MDA-5–IPS-1 Viral Sensing Pathway Induces Cancer Cell Death and Type I IFN-Dependent Antitumor Immunity.. Cancer Res. 2016;76:2166–2176.
    doi: 10.1158/0008-5472.CAN-15-2142pmc: PMC4873369pubmed: 26893477google scholar: lookup
  48. Ohman T, Rintahaka J, Kalkkinen N, Matikainen S, Nyman TA. Actin and RIG-I/MAVS Signaling Components Translocate to Mitochondria upon Influenza A Virus Infection of Human Primary Macrophages.. J. Immunol. 2009;182:5682–5692.
    doi: 10.4049/jimmunol.0803093pubmed: 19380815google scholar: lookup
  49. Jheng J-R, Ho J-Y, Horng J-T. ER stress, autophagy, and RNA viruses.. Front. Microbiol. 2014;5.
    pmc: PMC4122171pubmed: 25140166
  50. Batista IFC. A new Factor Xa inhibitor from Amblyomma cajennense with a unique domain composition.. Arch. Biochem. Biophys. 2010;493:151–156.
    doi: 10.1016/j.abb.2009.10.009pubmed: 19853573google scholar: lookup
  51. Araújo LMGde. Volume calculation of rats’ organs and its application in the validation of the volume relation between the abdominal cavity and the hernial sac in incisional hernias with ‘loss of abdominal domain’.. ABCD Arq. Bras. Cir. Dig. São Paulo 2014;27:177–181.
    doi: 10.1590/S0102-67202014000300004pmc: PMC4676367pubmed: 25184766google scholar: lookup
  52. Liao Y, Smyth GK, Shi W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote.. Nucleic Acids Res. 2013;41:e108–e108.
    doi: 10.1093/nar/gkt214pmc: PMC3664803pubmed: 23558742google scholar: lookup
  53. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.. Bioinformatics 2010;26:139–140.
    doi: 10.1093/bioinformatics/btp616pmc: PMC2796818pubmed: 19910308google scholar: lookup
  54. Durinck S. BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis.. Bioinformatics 2005;21:3439–3440.
    doi: 10.1093/bioinformatics/bti525pubmed: 16082012google scholar: lookup
  55. Shmelkov E, Tang Z, Aifantis I, Statnikov A. Assessing quality and completeness of human transcriptional regulatory pathways on a genome-wide scale.. Biol. Direct. 2011;6:15.
    doi: 10.1186/1745-6150-6-15pmc: PMC3055855pubmed: 21356087google scholar: lookup
  56. Croft D. The Reactome pathway knowledgebase.. Nucleic Acids Res. 2014;42:D472–D477.
    doi: 10.1093/nar/gkt1102pmc: PMC3965010pubmed: 24243840google scholar: lookup
  57. Fabregat A. The Reactome pathway Knowledgebase.. Nucleic Acids Res. 2016;44:D481–D487.
    doi: 10.1093/nar/gkv1351pmc: PMC4702931pubmed: 26656494google scholar: lookup
  58. Slenter DN. WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research.. Nucleic Acids Res. 2018;46:D661–D667.
    doi: 10.1093/nar/gkx1064pmc: PMC5753270pubmed: 29136241google scholar: lookup
  59. Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG as a reference resource for gene and protein annotation.. Nucleic Acids Res. 2016;44:D457–D462.
    doi: 10.1093/nar/gkv1070pmc: PMC4702792pubmed: 26476454google scholar: lookup
  60. Chen EY. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool.. BMC Bioinformatics 2013;14:128.
    doi: 10.1186/1471-2105-14-128pmc: PMC3637064pubmed: 23586463google scholar: lookup
  61. Kuleshov MV. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update.. Nucleic Acids Res. 2016;44:W90–W97.
    doi: 10.1093/nar/gkw377pmc: PMC4987924pubmed: 27141961google scholar: lookup
  62. Sergushichev A. An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation.. 2016.
    doi: 10.1101/060012google scholar: lookup
  63. Franceschini A. STRING v9.1: protein-protein interaction networks, with increased coverage and integration.. Nucleic Acids Res. 2013;41:D808–D815.
    doi: 10.1093/nar/gks1094pmc: PMC3531103pubmed: 23203871google scholar: lookup
  64. Gene Ontology Consortium. Gene Ontology Consortium: going forward.. Nucl Acids Res. 2015;43:D1049–D1056.
    doi: 10.1093/nar/gkᅹpmc: PMC4383973pubmed: 25428369google scholar: lookup
  65. Finn RD. The Pfam protein families database: towards a more sustainable future.. Nucleic Acids Res. 2016;44:D279–D285.
    doi: 10.1093/nar/gkv1344pmc: PMC4702930pubmed: 26673716google scholar: lookup
  66. Bastian M, Heymann S, Jacomy M. Gephi: An Open Source Software for Exploring and Manipulating Networks.. 2009.
  67. Gu Z, Gu L, Eils R, Schlesner M, Brors B. circlize implements and enhances circular visualization in R.. Bioinformatics 2014;30:2811–2812.
    doi: 10.1093/bioinformatics/btu393pubmed: 24930139google scholar: lookup
  68. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis.. BMC Bioinformatics 2008;9:1–13.
    doi: 10.1186/1471-2105-9-559pmc: PMC2631488pubmed: 19114008google scholar: lookup
  69. Russo PST. CEMiTool: a Bioconductor package for performing comprehensive modular co-expression analyses.. BMC Bioinformatics 2018;19.
    pmc: PMC5819234pubmed: 29458351
  70. Stark C. BioGRID: a general repository for interaction datasets.. Nucleic Acids Res. 2006;34:D535–D539.
    doi: 10.1093/nar/gkj109pmc: PMC1347471pubmed: 16381927google scholar: lookup

Citations

This article has been cited 9 times.
  1. Prado Sousa AC, Durán-Prado M, Villar M, González-García A, Szabó MPJ, de la Fuente J. Tick saliva protein fraction inhibits breast cancer by decreasing cell viability and promoting apoptosis in vitro. PLoS One 2025;20(9):e0331779.
    doi: 10.1371/journal.pone.0331779pubmed: 40961088google scholar: lookup
  2. Leal-Galvan B, Kumar D, Karim S, Saelao P, Thomas DB, Oliva Chavez A. A glimpse into the world of microRNAs and their putative roles in hard ticks. Front Cell Dev Biol 2024;12:1460705.
    doi: 10.3389/fcell.2024.1460705pubmed: 39376631google scholar: lookup
  3. Pimenta J, Prada J, Pires I, Cotovio M. Programmed Cell Death-Ligand 1 (PD-L1) Immunohistochemical Expression in Equine Melanocytic Tumors. Animals (Basel) 2023 Dec 22;14(1).
    doi: 10.3390/ani14010048pubmed: 38200779google scholar: lookup
  4. Šuran J, Radić B, Trevisan-Silva D, Cindrić M, Hozić A. First Proteome Analysis of Poplar-Type Propolis. Plant Foods Hum Nutr 2024 Mar;79(1):83-89.
    doi: 10.1007/s11130-023-01127-wpubmed: 38048032google scholar: lookup
  5. Morais KLP, Ciccone L, Stura E, Alvarez-Flores MP, Mourier G, Driessche MV, Sciani JM, Iqbal A, Kalil SP, Pereira GJ, Marques-Porto R, Cunegundes P, Juliano L, Servent D, Chudzinski-Tavassi AM. Structural and functional properties of the Kunitz-type and C-terminal domains of Amblyomin-X supporting its antitumor activity. Front Mol Biosci 2023;10:1072751.
    doi: 10.3389/fmolb.2023.1072751pubmed: 36845546google scholar: lookup
  6. Pimenta J, Prada J, Cotovio M. Equine Melanocytic Tumors: A Narrative Review. Animals (Basel) 2023 Jan 10;13(2).
    doi: 10.3390/ani13020247pubmed: 36670786google scholar: lookup
  7. Lobba ARM, Alvarez-Flores MP, Fessel MR, Buri MV, Oliveira DS, Gomes RN, Cunegundes PS, DeOcesano-Pereira C, Cinel VD, Chudzinski-Tavassi AM. A Kunitz-type inhibitor from tick salivary glands: A promising novel antitumor drug candidate. Front Mol Biosci 2022;9:936107.
    doi: 10.3389/fmolb.2022.936107pubmed: 36052162google scholar: lookup
  8. Jmel MA, Aounallah H, Bensaoud C, Mekki I, Chmelař J, Faria F, M'ghirbi Y, Kotsyfakis M. Insights into the Role of Tick Salivary Protease Inhibitors during Ectoparasite-Host Crosstalk. Int J Mol Sci 2021 Jan 17;22(2).
    doi: 10.3390/ijms22020892pubmed: 33477394google scholar: lookup
  9. Aounallah H, Bensaoud C, M'ghirbi Y, Faria F, Chmelar JI, Kotsyfakis M. Tick Salivary Compounds for Targeted Immunomodulatory Therapy. Front Immunol 2020;11:583845.
    doi: 10.3389/fimmu.2020.583845pubmed: 33072132google scholar: lookup
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.